Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related AKBA
This Week's First IPO: Global Blood Therapeutics Developing Drugs For Diseases Affecting Few
Why Akebia Therapeutics Is Worth $10 Per Share, But Needs More Visibility
Related AI
Top 4 Small-Cap Stocks In The Mortgage Investment Industry With The Highest EPS Growth Forecast For Next 5 Years
Is Sallie Mae (SLM) Likely to Miss Earnings This Season?

Analysts at Nomura initiated coverage on shares of Akebia Therapeutics (NASDAQ: AKBA) with a “buy” rating. The target price for Akebia Therapeutics is set to $39. Akebia Therapeutics' shares closed at $16.86 on Friday.

Credit Suisse initiated coverage on shares of Arlington Asset Investment (NYSE: AI) with a “neutral” rating. The target price for Arlington Asset Investment is set to $26. Arlington Asset Investment's shares closed at $25.65 on Friday.

SunTrust Robinson Humphrey initiated coverage on shares of Pandora Media (NYSE: P) with a “buy” rating. The target price for Pandora Media is set to $34. Pandora's shares closed at $25.31 on Friday.

Analysts at Stifel Nicolaus initiated coverage on shares of Q2 Holdings (NYSE: QTWO) with a “buy” rating. The target price for Q2 Holdings is set to $18. Q2 Holdings' shares closed at $13.68 on Friday.

Latest Ratings for AKBA

DateFirmActionFromTo
Aug 2015Morgan StanleyInitiates Coverage onEqual-weight
Jun 2015JMP SecuritiesInitiates Coverage onOutperform
May 2015Brean CapitalInitiates Coverage onBuy

View More Analyst Ratings for AKBA
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (AI + AKBA)

Get Benzinga's Newsletters